by April Breyer Menon | Sep 8, 2022
Download PDF Download...
by April Breyer Menon | Aug 31, 2022
Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee® (insulin glargine-yfgn), interchangeable with Lantus®...
by April Breyer Menon | Aug 5, 2022
Download PDF Download...
by April Breyer Menon | Jul 19, 2022
Venable’s Ha Kung Wong and April Breyer Menon break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape for the Center for Biosimilars. Precision medicine is changing the...
by April Breyer Menon | Jul 8, 2022
Download PDF Download...
by April Breyer Menon | Jun 7, 2022
Download PDF Download...